Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with metastatic non-small cell lung cancer (a type of lung cancer that has spread), confirmed by a tissue or cell sample, and who have not yet received chemotherapy or immunotherapy for their advanced disease
• People whose cancer has been confirmed as stage IV (advanced/spread) by a scan such as a CT, PET/CT, or MRI
• People whose treatment plan includes a combination of platinum-based chemotherapy and an immunotherapy drug that targets PD-1 or PD-L1
• People who received chemotherapy or radiation earlier for an early-stage diagnosis — this does not count as prior treatment for advanced disease, unless the cancer came back within 6 months of finishing that earlier treatment
• People whose cancer has at least one area that can be measured on scans, as judged by their treating doctor
• People aged 18 or older
• People with certain specific gene changes in their cancer (EGFR, BRAF, ALK, or ROS-1) may still be considered, provided their cancer progressed on, or they were unable to tolerate, an FDA-approved targeted therapy for that gene change
• People with a general health/activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities — confirm with trial site)
• People whose kidney function, liver function, and blood counts fall within acceptable ranges as tested by a blood test (specific values will be checked by the trial site)
• People who are willing and able to understand the trial requirements and sign a consent form

Who may not be able to join:

• People who have, or have recently had, another type of cancer — exceptions may include certain low-risk or previously treated cancers, such as some non-melanoma skin cancers, early-stage breast cancer, low-risk prostate cancer, or a cancer diagnosed 3 or more years ago that no longer requires active treatment
• People who have previously been treated with certain immunotherapy drugs that target PD-1, PD-L1, PD-L2, or similar immune system pathways
• People who have a serious or uncontrolled active infection that, in the treating doctor's opinion, could interfere with scan results
• People who have a medical condition, ongoing treatment, or abnormal test result that the treating doctor believes could affect the trial results or make participation unsafe or not in the person's best interest
• People who have an active autoimmune disease (where the immune system attacks the body) that currently requires medication to suppress or modify the immune system — note that simple hormone replacement therapies (such as thyroid hormone, insulin, or certain steroid replacements) are not considered in this category
• People who have active and symptomatic cancer spread to the brain or the lining of the brain — however, people with stable or previously treated brain spread may be considered, as long as they are not taking more than 10 mg of prednisone (or an equivalent steroid) per day

Important: Always verify eligibility with the trial site directly before applying.